Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria
Authors:
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1864 (3) , 668-675
Abstract
No abstract availableKeywords
Funding Information
- Rare Trait Hope Fund
- Vaincre l'AGU Foundation
This publication has 39 references indexed in Scilit:
- A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter AssaysPLOS Biology, 2013
- The role of nonsense-mediated decay in neuronal ceroid lipofuscinosisHuman Molecular Genetics, 2013
- Restoration of Cytoskeleton Homeostasis After Gigaxonin Gene Transfer for Giant Axonal NeuropathyHuman Gene Therapy, 2013
- Rescue of nonsense mutations by amlexanox in human cellsOrphanet Journal of Rare Diseases, 2012
- Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutationsJournal of Cellular Biochemistry, 2010
- Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compoundsProceedings of the National Academy of Sciences, 2010
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences, 2008
- New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapyHuman Genetics, 2006
- Dissection of the molecular pathology of aspartylglucosammuria provides the basis for DNA diagnostics and future therapeutic interventionsScandinavian Journal of Clinical and Laboratory Investigation, 1993
- In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutationGenomics, 1991